

# NACC New Investigator Project

## **The intersection of amyloid and cerebrovascular pathology: the perivascular space**

Erin Boespflug, Ph.D.



[boespfle@ohsu.edu](mailto:boespfle@ohsu.edu)

Assistant Professor, Neurology

Oregon Aging and Alzheimer's Disease Center




# The Neurovascular Unit




Modified from Jessen et al., *Neurochem Res.* 2015


# The perivascular space




Perivascular space



# enlarged perivascular space (ePVS)





Perivascular space





# ePVS were previously considered

...a benign clinical finding




# ePVS were previously considered

...a benign clinical finding




...or an artifact of tissue fixation



# ePVS : Clinical Relevance

ePVS burden is associated with:

- **cerebral small vessel disease**  
Patankar 2005, Potter 2015, Bouvy 2016
- **vascular disease risk factors:**  
lacunar stroke, hypertension,  
WMH Yakushiji 2014
- **CAA** Charidimou 2014, vanVeluw 2016




vanVeluw, JCBFM, 2016

# ePVS : Clinical Relevance


ePVS burden is associated with:

- cerebral small vessel disease  
Patankar 2005, Potter 2015, Bouvy 2016
- vascular disease risk factors:  
lacunar stroke, hypertension,  
WMH Yakushiji 2014
- CAA Charidimou 2014, vanVeluw 2016
- APOE4 status, cortical A $\beta$   
Roher 2003
- Alzheimer's disease status  
Ramirez 2015



Ramirez., JAD, 2015


# Clinical and Pathology correlates of ePVS



328 large (mean 16, SD 5.8  $\mu\text{m}$ ) vessels from:


Alzheimer's disease (N=10)  
mixed dementia (N=7)  
control (N=16)

# ePVS in AD and mixed dementia



Cases with Alzheimer's disease and with cerebrovascular disease have higher dilation of the perivascular space than do control cases.


# ePVS : Pathology correlates



Cases with AD pathology :  
hTau (A) and  
amyloid plaque (B)  
have greater ePVS  
than do cases  
without.


A qualitative  
increase in ePVS is  
observed in cases  
with vascular  
pathology (C, D)

# Amyloid $\beta$ clearance, not production is altered in sporadic AD




The brain **perivascular space** is a route of fluid flow serving to maintain brain homeostasis, including clearance of amyloid


Normal young



Aging



Disease




# NACC New Investigator Proposal

## Goals

- 1) Understand the extent to which clinical and pathological features of vascular-, amyloid-, and tau-based pathologies are associated with ePVS
  - 2) Begin to test the hypothesis that ePVS are a reflection of impaired waste clearance mechanisms
- Aim 1: **Clinical features**
    - **MRI**, age, cognitive function
  - Aim 2: **Neuropathology**
    - amyloid and tau, cerebrovascular disease
  - Aim 3: **Amyloid clearance**
    - increased cortical amyloid load (PET)
    - reduced amyloid in the cerebrospinal fluid (CSF)

# ePVS: Visualization on MRI


- Current gold standard
  - visual rating scales
    - single axial slice
    - category score based on severity (counts)
  - labor and time intensive
  - no volume or morphology information





“A major limitation to understanding the etiology and clinical relevance of ePVS is limited reliability in identification on MRI precluding unified research”

# ePVS detection goal: *intensity and morphology*

Clusters of CSF isointense voxels assessed  
on the basis of linear morphology



$r = 0.66$   
width = 6.76 mm,  
volume = 15 mm<sup>3</sup>




$r = 0.84$   
width = 3.53 mm,  
volume = 13 mm<sup>3</sup>

Clusters meet criteria if:

- MRI intensity matches ePVS profile *-and-*
- Morphology constraints match ePVS profile


# Refined segmentation approach : limited sequence MRI




# Dataset examples

**Low burden volume**


**T<sub>1</sub>**



**FLAIR**



**T<sub>1</sub> + PVS overlay**




Age = 82

WM volume = 489331.08 mm<sup>3</sup>

PVS volume = 707 mm<sup>3</sup>

PVS : WM volume = 0.14 %

PVS count = 53






Age = 63

WM volume = 454676.46 mm<sup>3</sup>

PVS volume = 1048 mm<sup>3</sup>

PVS : WM volume = 0.23 %

PVS count = 58



Age = 80

WM volume = 452869.55 mm<sup>3</sup>

PVS volume = 1716 mm<sup>3</sup>

PVS : WM volume = 0.38 %


PVS count = 136

**High burden volume**


# Dataset examples

Low burden  
volume


$T_1$



FLAIR



$T_1$  + PVS overlay





Age = 82

WM volume = 489331.08 mm<sup>3</sup>

PVS volume = 707 mm<sup>3</sup>

PVS : WM volume = 0.14 %

PVS count = 53



Age = 63




WM volume = 454676.46 mm<sup>3</sup>

PVS volume = 1048 mm<sup>3</sup>

PVS : WM volume = 0.23 %

PVS count = 58

High burden  
volume



Age = 80


WM volume = 452869.55 mm<sup>3</sup>

PVS volume = 1716 mm<sup>3</sup>

PVS : WM volume = 0.38 %

PVS count = 136

# Dataset examples



Age = 63

WM volume = 454676.46 mm<sup>3</sup>

PVS volume = 1048 mm<sup>3</sup>

PVS : WM volume = 0.23 %

PVS count = 58

\*Additional results slides have been omitted pending publication

# Thank you

## OHSU Neurology/Layton Aging & Alzheimer's Disease Center

Jeffrey Kaye

\*Lisa Silbert

Daniel Schwartz

Vanessa Cid

David Lahna

\*Randy Woltjer

Sarah Gothard

\*Hiroko Dodge

Natalie Roese

Robin Guariglia

Layton Center Staff

Research Participants

## NACC

Merilee Teylan

Maggie Dean

## OHSU

\*Bill Rooney

Josh Nickerson

Jeff Iliff (UW)

Matt Simon

## UC Davis

Carlie DeCarli

Baljeet Singh

## Funding

**National Alzheimer's Coordinating Center New Investigator Award, NIH**

**\*K01AG059842, 1R01AG036772, P30 AG008017, RO1 AG024059,**